For more information,
contact Dr. Ken Curry at (604) 818-8280











About The Company

RF Therapeutics Inc. is a research based company, developing novel strategies for non-invasive imaging of specific tissue types. Our technologies are focused on the detection of dead tissue using the imaging technique of Magnetic Resonance Imaging (MRI), Positrom Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT). Our lead products are injectable dyes, designed to show dead tissue in cases of heart attack and other ischemic events such as stroke, infarct and embolism. Currently, the medical profession has few, if any, tools for this kind of detection and the RF Therapeutics Inc. product line will greatly enhance the ability to detect, diagnose and act upon a wide range of disease areas. The lead compound, RF1106, is currently in proof of principle studies, leading to pre-clinical development. In addition, a pipeline of products is under investigation for MRI and other imaging techniques.